UBS Group’s Kairos Pharma KAPA Stock Holding History

UBS Group’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.69K	Buy	1,033 +139	+16%	+$289	﹤0.01%	10190
2026 Q2	$2.4K	Buy	+894	New	+$3.25K	﹤0.01%	9350
2025 Q4	–	Sell	-854	Closed	-$7K	–	11370
2025 Q3	$7K	Sell	854 -497	-37%	-$3.98K	﹤0.01%	8753
2025 Q2	$6.71K	Buy	1,351 +952	+239%	+$4.85K	﹤0.01%	9067
2025 Q1	$2.61K	Sell	399 -1,150	-74%	-$10.3K	﹤0.01%	9300
2024 Q4	$16.5K	Buy	+1,549	New	+$16.6K	﹤0.01%	8001

Other funds holding KAPA

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

UBS Group's KAPA Position: Q3 2026 in Review

UBS Group increased its Kairos Pharma (KAPA) stake by 16% in Q3 2026, buying an estimated $289 and bringing the position to 1,033 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #10190.

UBS Group first reported a position in KAPA in Q4 2024 and has held it in 6 quarters since. The position peaked at $16.5K in Q4 2024. 2 funds tracked by Wall St. Rank hold KAPA as of Q3 2026.

UBS Group held 1,033 shares of Kairos Pharma worth $1.69K as of Q3 2026.
UBS Group bought 139 Kairos Pharma shares in Q3 2026, an estimated $289.
Kairos Pharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10190 holding.
UBS Group first reported a position in Kairos Pharma in Q4 2024 and has held it in 6 quarters since.
UBS Group's Kairos Pharma position peaked at $16.5K in Q4 2024.
2 funds tracked by Wall St. Rank held Kairos Pharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.